Startup brief
Mega-Deals and Venture Expansion in Silicon Wadi
Anthropic halts a $6B acquisition while US venture giants deepen direct investments in Israeli AI, biotech, and defense startups.
Startup
Anthropic's withdrawal deprives Silicon Wadi of a marquee $6 billion exit — signaling tighter due diligence standards for mega-cap AI acquisitions.
BackgroundDecart was founded by IDF Unit 8200 veterans and created real-time generative video platforms along with software stacks that optimize graphics processor inference speed. Decart had previously raised $450 million at a $4 billion valuation from Nvidia and Sequoia.
- Anthropic walked away during final due diligence checks, halting what would have been the largest acquisition of an Israeli software company in history.
- Decart had rejected an earlier acquisition offer from Nvidia in favor of Anthropic's equity-heavy buyout proposal, leaving the startup with no immediate exit path.
- The deal's collapse reflects heightened caution among major AI labs regarding valuation metrics and intellectual property integration prior to public filings.
Startup
Wonderful's $5 billion valuation proves global venture firms will still pay top multiples for category-defining Israeli enterprise software.
BackgroundWonderful develops an enterprise operating system for autonomous digital agents that handle complex corporate workflows. The company reached an estimated $70 million annual recurring revenue run rate across 35 international markets.
- Existing backers Index Ventures, Bessemer Venture Partners, and IVP participated alongside $170 million in secondary share purchases from early employees.
- Funding will accelerate research into multi-agent orchestration while expanding corporate sales operations across North America and Europe to capture enterprise AI demand.
- The transaction represents one of the fastest venture valuation expansions in Israeli technology history, scaling the firm from seed stage to multi-billion-dollar valuation in 24 months.
Startup
Israeli academic and medical institutions are pooling $500 million to self-fund early drug discovery — stepping in where venture capital has pulled back.
BackgroundEarly-stage life sciences funding in Israel has contracted sharply over the past two years, leaving university research spin-outs struggling for seed capital. The hub aggregates clinical resources from major health funds including Clalit, Maccabi, and Sheba Medical Center.
- Former Bristol Myers Squibb executive Samuel Moed and Compugen chair Dr. Anat Cohen-Dayag were appointed to lead operations, bridging executive pharma experience with local clinical research.
- The center will provide early capital, laboratory infrastructure, and patent licensing support, helping early lab breakthroughs overcome the commercialization drop-off.
- Broad institutional backing from major health funds aims to reverse a multi-year decline in healthcare venture creation across Israeli research universities.
Startup
Swish's $250 million fund shows strong American institutional backing for early-stage Israeli deep-tech and dual-use defense founders.
BackgroundCasspi launched Swish Ventures to connect Israeli deep-tech founders with American institutional capital and corporate partners. The firm's portfolio includes 20 companies and eight unicorns, including Cognition AI and Wonderful.
- Institutional backers include US university endowments, public pension funds, and venture pioneer Sequoia Capital, solidifying American institutional LP commitment to Israeli tech.
- The fund plans to write initial checks averaging $20 million across 12 seed and Series A startups, targeting high-conviction leads rather than broad portfolio indexing.
- Investment focus areas prioritize industrial automation, defense systems, and governmental software infrastructure, tapping heightened global demand for dual-use technologies.
Startup
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
